Vaccines and antimicrobial resistance: from science to policy—summary and outcomes

In April 2024, the Royal Society convened a Science+ meeting in London on 'Vaccines and antimicrobial resistance: from science to policy'. The purpose was to review the science of how vaccines reduce antimicrobial resistance (AMR) and discuss policy in advancing development and equitable deployment of such vaccines. The meeting adopted a One Health approach with international speakers presenting from both human and veterinary perspectives. Presentations on Day 1 focused on scientific aspects of the AMR threat and the role of vaccines as counter measures. On Day 2, presentations covered associated policy implications based on this scientific understanding. A closing panel discussion looked towards the United Nations High-Level Meeting on AMR in New York in September 2024. This article is the closing contribution to an issue of Philosophical Transactions of the Royal Society B based on the meeting. It serves as a summary of the two days of proceedings, including key outcomes and recommendations, and provides an overall conclusion to the meeting. This article is part of the Royal Society Science+ meeting issue 'Vaccines and antimicrobial resistance: from science to policy'.

Authors

Institutions

Publication Details

Journal
Philosophical Transactions of the Royal Society B Biological Sciences
Published
2026-02-19
DOI
https://doi.org/10.1098/rstb.2025.0012
Primary Topic
Antibiotic Use and Resistance
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Vaccines and antimicrobial resistance: from science to policy—summary and outcomes

William P. Hausdorff, Mwelwa Chibuye, David C. Kaslow, Kelvin M. Abuga et al.
Philosophical Transactions of the Royal Society B Biological Sciences
Antibiotic Use and Resistance
article

Vaccines and antimicrobial resistance: from science to policy—summary and outcomes

William P. Hausdorff, Mwelwa Chibuye, David C. Kaslow, Kelvin M. Abuga, Anthony McDonnell, Javier Yugueros-Marcos, Calman A. MacLennan, Richard Hatchett, Rory P. Cooney, Peter Borriello, Roberto Marcello La Ragione, Duncan J. Colquhoun, Renée Larocque, Katherine L O'Brien, F. Descamps, Ed T. Buurman, Megan E. Carey, Erica Carman Westwood, Rino Rappuoli, Mateusz Hasso-Agopsowicz, Terry W. Komo, Richard A. Adegbola, Ramanan Laxminarayan, Gordon Dougan, Laura M.A. Oliveira, Marta Tufet, Farah N. Qamar, Sally C. Davies, Annaliesa S. Anderson
article en

Abstract

In April 2024, the Royal Society convened a Science+ meeting in London on 'Vaccines and antimicrobial resistance: from science to policy'. The purpose was to review the science of how vaccines reduce antimicrobial resistance (AMR) and discuss policy in advancing development and equitable deployment of such vaccines. The meeting adopted a One Health approach with international speakers presenting from both human and veterinary perspectives. Presentations on Day 1 focused on scientific aspects of the AMR threat and the role of vaccines as counter measures. On Day 2, presentations covered associated policy implications based on this scientific understanding. A closing panel discussion looked towards the United Nations High-Level Meeting on AMR in New York in September 2024. This article is the closing contribution to an issue of Philosophical Transactions of the Royal Society B based on the meeting. It serves as a summary of the two days of proceedings, including key outcomes and recommendations, and provides an overall conclusion to the meeting. This article is part of the Royal Society Science+ meeting issue 'Vaccines and antimicrobial resistance: from science to policy'.

Philosophical Transactions of the Royal Society B Biological SciencesVol. 381(1944)
Boston University (US), Aga Khan University (PK), University of London (GB), Birmingham City University (GB), International Development Research Centre (CA), World Health Organization - Pakistan (PK), Centre for Infectious Disease Research in Zambia (ZM), Program for Appropriate Technology in Health (US), Department of Health and Social Care (GB), Gavi (CH), Center for Global Development (US), United States Food and Drug Administration (US), Pfizer (United States) (US), University of Cambridge (GB), University of Surrey (GB), Kenya Medical Research Institute (KE), Fondazione Monte dei Paschi di Siena (IT), University College Birmingham (GB), University of Alabama at Birmingham (US), University of Oxford (GB), Directorate of Health (IS), London School of Hygiene & Tropical Medicine (GB), Bridge University (SS), Coalition for Epidemic Preparedness Innovations (US), Coalition for Epidemic Preparedness Innovations (NO), Amsterdam Institute for Global Health and Development (NL), Aga Khan University (TZ), Education Trust (US), CNR de la Résistance aux Antibiotiques (FR), Centre for Global Health Research (CA), Health Research and Educational Trust (US), Food and Drug Administration (TH), BH Consulting (Ireland) (IE), Zoetis (Belgium) (BE), Norwegian Veterinary Institute (NO), Nigerian Institute of Medical Research (NG), Fundação Oswaldo Cruz (BR), University of Birmingham (GB), Food Standards Agency (GB), Wellcome Trust (GB), Organisation Mondiale de la Santé Animale (FR)
UK Research and Innovation, Department of Health and Social Care, Medical Research Council
Openalex Percentile: Top 45%
Antibiotic Use and Resistance
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.